Cosmo Pharmaceuticals NV (XSWX:COPN) 3-Year Revenue Growth Rate : 9.60% (As of Jun. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Cosmo Pharmaceuticals NV 3-Year Revenue Growth Rate?

Cosmo Pharmaceuticals NV's Revenue per Share for the six months ended in Jun. 2023 was CHF2.64.

During the past 12 months, Cosmo Pharmaceuticals NV's average Revenue per Share Growth Rate was 38.80% per year. During the past 3 years, the average Revenue per Share Growth Rate was 9.60% per year. During the past 5 years, the average Revenue per Share Growth Rate was 0.20% per year. During the past 10 years, the average Revenue per Share Growth Rate was -0.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of Cosmo Pharmaceuticals NV was 32.00% per year. The lowest was -28.20% per year. And the median was -1.75% per year.

Competitive Comparison of Cosmo Pharmaceuticals NV's 3-Year Revenue Growth Rate

For the Drug Manufacturers - General subindustry, Cosmo Pharmaceuticals NV's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cosmo Pharmaceuticals NV's 3-Year Revenue Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cosmo Pharmaceuticals NV's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Cosmo Pharmaceuticals NV's 3-Year Revenue Growth Rate falls into.

Cosmo Pharmaceuticals NV 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Cosmo Pharmaceuticals NV (XSWX:COPN) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Cosmo Pharmaceuticals NV 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Cosmo Pharmaceuticals NV's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Cosmo Pharmaceuticals NV (XSWX:COPN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cosmo Pharmaceuticals NV (XSWX:COPN) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

CMOPF:USA COPNz:UK C43:Germany

Address

Sir John Rogerson’s Quay, Riverside II, Dublin, IRL, 2

Website

https://www.cosmopharma.com

Cosmo Pharmaceuticals NV is a pharmaceutical company with a focus on gastrointestinal diseases, dermatology and healthtech. The company develops and manufactures products that are distributed globally by its partners. Products that the company has developed include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo for the treatment of travellers' diarrhoea (TD) and Winlevi for the treatment of acne. Product pipeline includes Breezula, GI Genius, Methylene blue MMX, Aemcolo, CB-03-10 and CB-01-33.

Cosmo Pharmaceuticals NV (XSWX:COPN) Headlines

No Headlines